Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Probiotic cocktail aims to soothe Year-Round allergies

NCT ID NCT07157462

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study tests whether a daily probiotic blend can improve quality of life for adults with persistent allergies to dust mites, cats, or dogs. For 12 weeks, 98 participants will take either the probiotic or a placebo and track their symptoms and antihistamine use. The goal is to see if the probiotic reduces allergy severity and boosts daily well-being.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

97 people

The number who actually took part.

Started

Sep 2025

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years * Willing and able to provide informed consent in French * Persistent perennial allergic rhinitis induced by a least one perennial allergen in the last two years. * Positive skin prick test ≥5 mm for any of the following allergens: cat, dog and mites * Mean global score of miniRQLQ ≥ 2 * TSS score of at least 7 * Willing to discontinue consumption of fermented foods, probiotics (e.g., yogurts with live, active cultures or supplements), prebiotics or immune-enhancing supplements (e.g., Echinacea or fish oil). * Agreement on not starting new medication during the intervention (rescue medication excepted) * Women of childbearing potential with a negative pregnancy test throughout the study period and highly effective contraception: oral contraceptives, condom with spermicide, intrauterine device, bilateral tubal ligation, vasectomized partner Exclusion Criteria: * Non-allergic rhinitis * Use of any prohibited medication (any systemic corticosteroids, androgens such as testosterone, or high doses of anti-inflammatory drugs: i.e., aspirin in doses 600 mg/d regularly) at the time of enrolment * Use of other probiotics-containing and prebiotics-containing products during the intervention period and 4 weeks before study start * Use of any antibiotics 6 weeks before randomization * Nasal polyposis * Currently enrolled in another intervention study (except observational studies) * Critically or terminally ill or admitted to the ICU * Had received chemotherapy or other immune-suppressing therapy within the previous year. * Other conditions that according to the investigator might interfere with the evaluation of the study objectives * Patients being treated for or had any of the following physician-diagnosed diseases or conditions: HIV; immune modulating diseases (autoimmune disease, hepatitis, cancer, etc.); kidney disease; pancreatitis; pulmonary disease; hepatic or biliary disease; or gastrointestinal diseases or conditions, such as diverticulitis, ulcerative colitis, Crohn's disease, Celiac disease, short bowel disease, ileostomy, or colostomy, but not including gastroesophageal reflux disease, * Subjects with a low compliance rate (appreciated by the investigator) during the run-in period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Perennial allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ALYATEC clinical center

    Strasbourg, Alyatec, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.